keyword
MENU ▼
Read by QxMD icon Read
search

Prostate pet

keyword
https://www.readbyqxmd.com/read/29345442/lung-uptake-of-fluorine-18-fluoroethyl-choline-pet-ct-in-patients-with-prostate-cancer
#1
Daniele A Pizzuto, Salvatore Annunziata, Francesco P Ieria, Carmelo Caldarella, Maria A Isgrò, Valerio Lanni, Gaia Bencivenga, Vittoria Rufini, Alessandro Giordano
BACKGROUND: Metastatic spreading to the lungs is a negative prognostic factor in patients with prostate cancer (PC). Aim of our study was to assess the prevalence of lung PC metastases in patients with fluorine-18 fluoroethyl-choline (F-18-FECh) PET-CT positive lung lesions and the role of Gleason Score (GS) and common biochemical markers in predicting metastatic spreading to the lungs. METHODS: We retrospectively evaluated the scans of 1283 patients ongoing (F-18-FECh) PET-CT for PC between May 2010 and July 2014...
January 17, 2018: Quarterly Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29344901/imaging-characteristics-and-first-experience-of-68ga-thp-psma-a-novel-probe-for-rapid-kit-based-ga-68-labeling-and-pet-imaging-comparative-analysis-with-68ga-psma-i-t
#2
Thorsten Derlin, Sebastian Schmuck, Cathleen Juhl, Steffi Teichert, Johanna Zörgiebel, Hans-Jürgen Wester, Sophie M Schneefeld, Almut C A Walte, James T Thackeray, Tobias L Ross, Frank M Bengel
PURPOSE: [68Ga]Trishydroxypyridinone (THP)-prostate-specific membrane antigen (PSMA) is a novel tracer that can be labeled in one step by cold reconstitution of a kit with unprocessed generator eluate, targeting PSMA via the lysine-urea-glutamate (KuE) motif. The aim of this study was to evaluate the human imaging characteristics of [68Ga]THP-PSMA. PROCEDURES: [68Ga]THP-PSMA positron emission tomography (PET)/x-ray computed tomography (CT) was performed in 25 patients with biochemical recurrence after radical prostatectomy for prostate cancer...
January 17, 2018: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
https://www.readbyqxmd.com/read/29344704/-the-role-of-psma-pet-ct-in-patients-with-metastatic-prostate-cancer
#3
REVIEW
J von Hardenberg, K-A Büsing, P Nuhn, M Ritter
Prostate-specific membrane antigen (PSMA) positron emission tomography-computed tomography (PET-CT) imaging for the localization of prostate cancer is increasingly available in Germany. The advances and limitations in different disease stages are reviewed. As the clinical relevance of oligometastatic disease in primary cancer detected by PSMA PET-CT imaging is not yet completely understood, it should only be used in clinical trials. In recurrent prostate cancer after therapy with curative intent, PSMA PET-CT shows encouraging potential for the planning of salvage therapy...
January 17, 2018: Der Radiologe
https://www.readbyqxmd.com/read/29344682/68ga-prostate-specific-membrane-antigen-psma-positron-emission-tomography-pet-for-primary-staging-of-high-risk-prostate-cancer-a-systematic-review
#4
Julia Corfield, Marlon Perera, Damien Bolton, Nathan Lawrentschuk
PURPOSE: To systematically review currently available data on 68Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) used for the primary staging of high-risk prostate cancer. METHODS: We performed critical reviews of EMBASE, Web of Science (including MEDLINE) and Cochrane databases in October 2016 according to the Preferred Reporting Items for Systematic Review and Meta-analysis statement. We included studies that utilized 68Ga-PSMA PET for primary staging of prostate cancer...
January 17, 2018: World Journal of Urology
https://www.readbyqxmd.com/read/29343908/pet-ct-and-pet-mr-in-urological-cancers-other-than-prostate-cancer-an-update-on-state-of-the-art
#5
REVIEW
Abdul Razik, Chandan Jyoti Das, Sanjay Sharma
Hybrid positron emission tomography with computed tomography (PET/CT) and magnetic resonance imaging (PET/MRI) have enabled the combination of morphologic and functional imaging with the promise of providing better information in guiding therapy. Further advance has been made in the past decade with the development of newer radiotracers and optimization of the technical aspects. We performed a search in PubMed, Scopus, and Google Scholar for peer-reviewed literature concerning the advances and newer developments in the imaging of nonprostate urologic cancers between 2005 and 2017...
January 2018: Indian Journal of Urology: IJU: Journal of the Urological Society of India
https://www.readbyqxmd.com/read/29340038/diagnostic-performance-of-68gallium-psma-11-pet-ct-to-detect-significant-prostate-cancer-and-comparison-with-18fec-pet-ct
#6
Manuela A Hoffmann, Matthias Miederer, Helmut J Wieler, Christian Ruf, Frank M Jakobs, Mathias Schreckenberger
Background: Radiolabeled prostate-specific membrane antigen (PSMA) has proven to be a highly accurate method to detect recurrence and metastases of prostate cancer, but only sparse data is available about its performance in the diagnosis of clinically significant primary prostate cancer. Methods: We compared 68Ga-PSMA-11 PET/CT in 25 patients with 18FEC PET/CT in 40 patients with suspected prostate carcinoma based on an increased PSA level.The PET/CT results were compared with the histopathologic Gleason Score (GS) of biopsies...
December 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/29333958/focal-mri-guided-salvage-high-dose-rate-brachytherapy-in-patients-with-radiorecurrent-prostate-cancer
#7
Metha Maenhout, Max Peters, Marco van Vulpen, Marinus A Moerland, Richard P Meijer, Maurice A A J van den Bosch, Paul L Nguyen, Steven J Frank, Jochem R N van der Voort van Zyp
INTRODUCTION: Whole-gland salvage treatment of radiorecurrent prostate cancer has a high rate of severe toxicity. The standard of care in case of a biochemical recurrence is androgen deprivation treatment, which is associated with morbidity and negative effects on quality of life. A salvage treatment with acceptable toxicity might postpone the start of androgen deprivation treatment, might have a positive influence on the patients' quality of life, and might even be curative. Here, toxicity and biochemical outcome are described after magnetic resonance imaging-guided focal salvage high-dose-rate brachytherapy in patients with radiorecurrent prostate cancer...
December 2017: Technology in Cancer Research & Treatment
https://www.readbyqxmd.com/read/29333469/utility-of-f-18-fdg-pet-ct-for-detection-of-bone-marrow-metastases-in-prostate-cancer-patients-treated-with-radium-223
#8
Kaoru Maruyama, Keita Utsunomia, Takahiro Nakamoto, Shigenari Kawakita, Takashi Murota, Noboru Tanigawa
A 76-year-old man with symptomatic bone metastases from castration-resistant prostate cancer underwent Radium-223-dichloride (Ra-223) therapy. Before Ra-223 therapy, he had normal peripheral blood cell counts. Ra-223 therapy relieved his shoulder and low back pain. The elevation of the serum prostate-specific antigen (PSA), doubling every month during Ra-223 therapy, suggested a PSA flare or relapse. Some lesions showed decrease and some lesions showed increase on Tc-99m hydroxymethylene diphosphonate bone scintigraphy at two weeks after the third injection of Ra-223 therapy...
2018: Asia Oceania Journal of Nuclear Medicine & Biology
https://www.readbyqxmd.com/read/29331524/strategies-and-technical-challenges-for-imaging-oligometastatic-disease-recommendations-from-the-european-organisation-for-research-and-treatment-of-cancer-imaging-group
#9
REVIEW
Nandita M deSouza, Yan Liu, Arturo Chiti, Daniela Oprea-Lager, Géraldine Gebhart, Bernard E Van Beers, Ken Herrmann, Frederic E Lecouvet
Patients with oligometastatic disease (OMD) often have controllable symptoms, and cures are possible. Technical improvements in surgery and radiotherapy have introduced the option of metastasis-directed ablative therapies as an adjunct or alternative to standard-of-care systemic therapies. Several clinical trials and registries are investigating the benefit of these therapeutic approaches across several cancer sites. This requires that patients are correctly included and followed with appropriate imaging. This article discusses the evidence and offers recommendations for the implementation of standard-of-care (Response Evaluation Criteria in Solid Tumours measurements on computed tomography [CT], magnetic resonance imaging [MRI] and bone scintigraphy) and advanced imaging modalities (functional, metabolic and radionuclide targeted) for identifying and following up patients with OMD...
January 10, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29327929/development-of-candidates-for-pet-imaging-of-ghrelin-receptor-in-disease-design-synthesis-and-evaluation-of-fluorine-bearing-quinazolinone-derivatives
#10
Jin-Qiang Hou, Michael S Kovacs, Savita Dhanvantari, Leonard G Luyt
Molecular imaging with PET (Positron Emission Tomography) is an attractive platform for non-invasive detection and assessment of disease. The development of a PET imaging agent targeting the ghrelin receptor (growth hormone secretagogue receptor type 1a or GHS-R1a) has the potential to lead to the detection and assessment of the higher than normal expression of GHS-R1a in diseases such as prostate, breast, and ovarian cancer. To enable the development of 18F radiopharmaceuticals, we have designed and synthesized three series of quinazolinone derivatives, resulting in the identification of two compound (5i, 17) with sub-nanomolar binding affinity and one fluorine-bearing compound (10b) with picomolar binding affinity (20 pM), representing the highest binding affinity for GHS-R1a reported to date...
January 12, 2018: Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/29326358/targeted-alpha-therapy-of-mcrpc-with-225actinium-psma-617-swimmer-plot-analysis-suggests-efficacy-regarding-duration-of-tumor-control
#11
Clemens Kratochwil, Frank Bruchertseifer, Hendrik Rathke, Markus Hohenfellner, Frederik L Giesel, Uwe Haberkorn, Alfred Morgenstern
The aim of this evaluation is to identify first indicators regarding the efficacy of 225Ac-PSMA-617 therapy in a retrospectively analyzed group of patients. Methods: Forty patients with metastatic castration-resistant prostate cancer were selected for treatment with 3 cycles of 100 kBq/kgBW 225Ac-PSMA-617 in 2 months intervals. Prostate-specific antigen (PSA) and blood cell count were measured every 4 weeks. Prostate-specific membrane antigen (PSMA)-PET/CT or PSMA-SPECT/CT were used for baseline staging and imaging follow-up at month six...
January 11, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29324926/risk-stratification-and-staging-in-prostate-cancer-with-prostatic-specific-membrane-antigen-pet-ctobjective-a-one-stop-shop
#12
Manoj Gupta, Partha Sarathi Choudhury, Sudhir Rawal, Harish Chandra Goel, Amitabh Singh, Vineet Talwar, Saroj Kumar Sahoo
OBJECTIVE: Current imaging modalities for prostate cancer (PC) had limitations for risk stratification and staging. Magnetic resonance imaging (MRI) frequently underestimated lymphatic metastasis while bone scintigraphy often had diagnostic dilemmas. Prostatic specific membrane antigen (PSMA) positron emission tomography-computed tomography (PET/CT) has been remarkable in diagnosing PC recurrence and staging. We hypothesized it can become one-stop-shop for initial risk stratification and staging...
September 2017: Hellenic Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/29323548/18f-fluorocholine-pet-whole-body-mri-in-the-staging-of-high-risk-prostate-cancer
#13
Ur Metser, Alejandro Berlin, Jaydeep Halankar, Grainne Murphy, Kartik S Jhaveri, Sangeet Ghai, Noam Tau
OBJECTIVE: The purpose of this study was to determine whether integrated 18F-fluorocholine (FCH) PET whole-body MRI (PET/WBMRI) depicts lymph node and distant metastases in patients with high-risk prostate cancer more frequently than does conventional staging. SUBJECTS AND METHODS: A prospective study included 58 patients with untreated high-risk prostate cancer. After conventional staging (CT and bone scintigraphy), patients underwent FCH PET/WBMRI (n = 10) or FCH PET/CT and WBMRI (n = 48)...
January 11, 2018: AJR. American Journal of Roentgenology
https://www.readbyqxmd.com/read/29320333/prostate-specific-membrane-antigen-pet-clinical-utility-in-prostate-cancer-normal-patterns-pearls-and-pitfalls
#14
Michael S Hofman, Rodney J Hicks, Tobias Maurer, Matthias Eiber
Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein that is overexpressed in prostate cancer. Radiolabeled small molecules that bind with high affinity to its active extracellular center have emerged as a potential new diagnostic standard of reference for prostate cancer, resulting in images with extraordinary tumor-to-background contrast. Currently, gallium 68 (68Ga)-PSMA-11 (or HBED-PSMA) is the most widely used radiotracer for PSMA positron emission tomography (PET)/computed tomography (CT) or PSMA PET/magnetic resonance (MR) imaging...
January 2018: Radiographics: a Review Publication of the Radiological Society of North America, Inc
https://www.readbyqxmd.com/read/29313360/diagnostic-bone-imaging-in-patients-with-prostate-cancer-patient-experience-and-acceptance-of-naf-pet-ct-choline-pet-ct-whole-body-mri-and-bone-spect-ct
#15
Eva Dyrberg, Emil L Larsen, Helle W Hendel, Henrik S Thomsen
Background Patient acceptance is an important factor when implementing imaging methods in clinical practice in line with availability, diagnostic accuracy, and cost-effectiveness. Purpose To investigate patient experience and acceptance regarding18F-sodium fluoride (NaF) positron emission tomography/computed tomography (PET/CT), 11 C-choline-PET/CT, whole-body magnetic resonance imaging (WB-MRI), and 99mTc-hydroxymethane diphosphonate (HDP) single photon emission/computed tomography (SPECT/CT). Material and Methods One hundred and forty-nine patients with prostate cancer filled in a questionnaire regarding their experience of the imaging procedures they had been undergoing as part of a diagnostic accuracy study...
January 1, 2018: Acta Radiologica
https://www.readbyqxmd.com/read/29308527/psa-stratified-detection-rates-for-68ga-thp-psma-a-novel-probe-for-rapid-kit-based-68ga-labeling-and-pet-imaging-in-patients-with-biochemical-recurrence-after-primary-therapy-for-prostate-cancer
#16
Thorsten Derlin, Sebastian Schmuck, Cathleen Juhl, Johanna Zörgiebel, Sophie M Schneefeld, Almut C A Walte, Katja Hueper, Christoph A von Klot, Christoph Henkenberens, Hans Christiansen, James T Thackeray, Tobias L Ross, Frank M Bengel
PURPOSE: [68Ga]Tris(hydroxypyridinone)(THP)-PSMA is a novel radiopharmaceutical for one-step kit-based radiolabelling, based on direct chelation of 68Ga3+ at low concentration, room temperature and over a wide pH range, using direct elution from a 68Ge/68Ga-generator. We evaluated the clinical detection rates of [68Ga]THP-PSMA PET/CT in patients with biochemically recurrent prostate cancer after prostatectomy. METHODS: Consecutive patients (n=99) referred for evaluation of biochemical relapse of prostate cancer by [68Ga]THP-PSMA PET/CT were analyzed retrospectively...
January 7, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29303359/bayesian-penalised-likelihood-reconstruction-q-clear-of-18f-fluciclovine-pet-for-imaging-of-recurrent-prostate-cancer-semi-quantitative-and-clinical-evaluation
#17
Eugene J Teoh, Daniel R McGowan, David M Schuster, Maria Tsakok, Fergus V Gleeson, Kevin M Bradley
OBJECTIVE: 18F-Fluciclovine (FACBC) is an amino acid PET radiotracer approved for recurrent prostate cancer imaging. We investigate the use of Bayesian penalised likelihood (BPL) reconstruction for 18F-fluciclovine PET. METHODS: Fifteen 18F-fluciclovine scans were reconstructed using OSEM, OSEM+point spread function modeling (PSF) and BPL using β values 100-600. Lesion SUVmax, organ SUVmean and standard deviation were measured. De-identified reconstructions (OSEM, PSF, BPL using β200-600) from 10 cases were visually analysed by two readers who indicated their most and least preferred reconstructions, and scored overall image quality (IQ), noise level, background marrow IQ and lesion conspicuity...
January 5, 2018: British Journal of Radiology
https://www.readbyqxmd.com/read/29301928/the-utility-of-pet-ct-in-external-radiation-therapy-planning-of-prostate-cancer
#18
Jeremie Calais, Minsong Cao, Nicholas G Nickols
Radiotherapy and radical prostatectomy are the definitive treatment options for patients with localized prostate cancer. A rising PSA after radical prostatectomy indicates prostate cancer recurrence, and these patients may still be cured with salvage radiotherapy. To maximize chance for cure, irradiated volumes should completely encompass the extent of disease. Therefore, accurate estimation of the location of disease is critical for radiotherapy planning in both the definitive and salvage settings. Conventional imaging for prostate cancer has limited sensitivity for detection of disease both at initial staging and at biochemical recurrence...
January 4, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29291425/lymphangitic-carcinomatosis-from-prostate-cancer-identified-with-gallium-68-prostate-specific-membrane-antigen-positron-emission-tomography-imaging
#19
Victor Tang, Patrina Campbell, David A Pattison
Lymphangitic carcinomatosis (LC) refers to the rare process of diffuse malignant invasion of the pulmonary lymphatics. We describe the first reported case of LC visualised with Gallium-68 Prostate-Specific Membrane Antigen positron emission tomography (68Ga-PSMA-PET) and its clinical significance in a 53-year-old man with prostate carcinoma. This case highlights the ability of 68Ga-PSMA-PET for prostate carcinoma characterisation and the importance of always considering atypical patterns of metastatic disease...
December 29, 2017: Urology
https://www.readbyqxmd.com/read/29284672/hospice-admission-and-survival-following-18f-fluoride-pet-performed-for-evaluation-of-osseous-metastatic-disease-in-the-national-oncologic-pet-registry
#20
Ilana F Gareen, Bruce E Hillner, Lucy Hanna, Rajesh Makineni, Fenghai Duan, Anthony F Shields, Rathan M Subramaniam, Barry Siegel
We have previously reported that positron emission tomography using 18F-fluoride (NaF-PET) for assessment of osseous metastatic disease was associated with substantial changes in intended management in Medicare beneficiaries participating in the National Oncologic PET Registry (NOPR). Here, we use Medicare administrative data to examine the association between NaF-PET results and hospice claims within 180 days and 1-year survival. Methods: We classified NOPR NaF-PET results linked to Medicare claims by imaging indication [initial staging (IS); detection of suspected first osseous metastasis (FOM); suspected progression of osseous metastasis (POM); or treatment monitoring (TM)] and type of cancer (prostate, lung, breast or other)...
December 28, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
keyword
keyword
11205
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"